STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
conferences
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Stock Data

4.49M
40.68M
15.72%
2.43%
7.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/